THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. Thirteen of the eval...
Original Article: Amgen Drug Shrinks 54% Of Lung Cancer Tumors In Study